BowelScreen Aotearoa™ uses the ColoVantage Home immunochemical test kit designed and manufactured by Enterix Australia (Clinical Genomics).
 
Over one million test kits are exported from Australia to the United States annually. The test has been approved by the US Food and Drug Administration (FDA), the Therapeutic Goods Administration (TGA) in Australia and is listed on the New Zealand Web Assisted Notification of Devices (NZ WAND).
 
The ColoVantage Home test has 98% specificity (a 2% false positive rate) and 87.5% sensitivity for bowel cancer, quite the opposite of claims that the test carries a ‘large degree of false positives and false negatives’. In fact, detection rates for advanced adenomas and cancer are significantly higher for iFOBT than guaiac faecal occult blood tests (gFOBT).
 
Clinical papers referencing this data are available upon request (please email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it ). The clinical trials using the ColoVantage Home test have predominantly been run in Australia.
 
The test also has a unique patented sampling method, requires no faecal handling and has inherent sample stability as it uses a dried water sample and no buffer solution. BowelScreen Aotearoa™ promotes iFOBT screening for asymptomatic consumers.
 
Consumers experiencing symptoms or those with a personal or family history are clearly advised to visit their GP in the first instance.
 
GPs play a critical role in the BowelScreen Aotearoa™ pathway. All results, both positive and negative, are sent to the consumer’s GP as well as the consumer. Tests will not be analysed without the consumer nominating a GP.
 
The ColoVantage Home test has been used in Australia to screen asymptomatic patients for over ten years. Furthermore, during this time, the test has been prescribed by over 5,000 Australian GPs every year.
 
We welcome the constructive involvement of health professionals with BowelScreen Aotearoa™ as we work towards more informed consumers and better health outcomes for bowel cancer patients.
 
email this page

Bowel Screening Pilot

Please note: The New Zealand Government is gradually phasing in a National Bowel Screening Program to be completed by 2021. New Zealander’s aged 60 to 74 years who are eligible to for publicly funded health care will receive an invitation to take part in the screening program when it becomes available in their DHB. Eligible New Zealanders will receive a free faecal immunochemical test (FIT) in the mail and are encouraged to complete and return it. For information regarding start dates of each phase please visit www.timetoscreen.nz or phone 0800 924 432.

Alternatively, anyone can take part in an annual screening by purchasing a BowelScreen Aotearoa™ kit at their local participating pharmacy.